Aurinia Pharmaceuticals Inc.

NasdaqGM:AUPH Stock Report

Market Cap: US$1.2b

Aurinia Pharmaceuticals Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGM:AUPH Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
09 Dec 24BuyUS$10,822,000Tang Capital Management, LLCCompany1,200,000US$9.09
06 Dec 24BuyUS$6,277,000Tang Capital Management, LLCCompany700,000US$9.01
06 Sep 24BuyUS$37,956,904Tang Capital Management, LLCCompany6,060,843US$7.20
06 Aug 24SellUS$96,902Scott HabigIndividual18,249US$5.31
21 May 24SellUS$30,146Daniel BillenIndividual5,252US$5.74
21 May 24SellUS$2,985Brinda BalakrishnanIndividual520US$5.74
21 May 24SellUS$32,316R. Mackay-DunnIndividual5,630US$5.74
21 May 24SellUS$32,201Jill LeversageIndividual5,610US$5.74
21 May 24SellUS$28,390David R. JayneIndividual4,946US$5.74
06 Mar 24SellUS$99,551Scott HabigIndividual17,777US$5.60
06 Mar 24SellUS$194,942Joseph MillerIndividual34,811US$5.60
06 Mar 24SellUS$711,094Peter GreenleafIndividual126,981US$5.60
06 Mar 24SellUS$323,372Stephen RobertsonIndividual57,745US$5.60
06 Mar 24SellUS$224,064Matthew DonleyIndividual40,665US$5.51
27 Feb 24SellUS$30,073Volker KnappertzIndividual4,930US$6.10
20 Feb 24SellUS$137,800Volker KnappertzIndividual25,146US$5.48
20 Feb 24SellUS$86,951Scott HabigIndividual15,867US$5.48

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of AUPH?
Owner TypeNumber of SharesOwnership Percentage
Public Companies1,123,6080.785%
Individual Insiders2,156,1891.51%
Hedge Funds8,200,0005.73%
Institutions57,944,75840.5%
General Public73,754,71451.5%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 39.88% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
6.33%
BlackRock, Inc.
9,065,931US$75.6m-2.22%no data
5.89%
Tang Capital Management, LLC
8,429,500US$70.3m16.6%5.2%
5.73%
Armistice Capital LLC
8,200,000US$68.4m-26.4%1.62%
4.47%
ILJIN SNT Co., Ltd
6,396,283US$53.3m0%no data
2.77%
New Enterprise Associates, Inc.
3,969,834US$33.1m0%1.91%
2.06%
State Street Global Advisors, Inc.
2,945,060US$24.6m2.26%no data
1.47%
Goldman Sachs Asset Management, L.P.
2,105,049US$17.6m-2.06%no data
1.23%
Geode Capital Management, LLC
1,766,370US$14.7m0.16%no data
1.13%
The Vanguard Group, Inc.
1,617,835US$13.5m5.11%no data
0.97%
Morgan Stanley, Investment Banking and Brokerage Investments
1,388,061US$11.6m55%no data
0.94%
Teachers Insurance and Annuity Association-College Retirement Equities Fund
1,347,796US$11.2m-25.1%no data
0.82%
Rock Springs Capital Management LP
1,179,740US$9.8m0%0.33%
0.78%
Lotte Chemical Corporation
1,123,608US$9.4m0%no data
0.7%
Northern Trust Global Investments
995,689US$8.3m1.6%no data
0.52%
Charles Schwab Investment Management, Inc.
744,050US$6.2m13.8%no data
0.5%
Kyoung Huh Sae
722,740US$6.0m0%no data
0.46%
Citigroup Inc.,Banking and Securities Investments
654,186US$5.5m-7.35%no data
0.43%
Eun Huh Seoung
614,333US$5.1m0%no data
0.41%
Trexquant Investment LP
583,022US$4.9m139%0.06%
0.4%
AQR Capital Management, LLC
567,045US$4.7m181%0.01%
0.39%
Segall Bryant & Hamill, LLC
562,775US$4.7m1.63%0.06%
0.38%
Societe Generale, Securities Investments
547,727US$4.6m4,310%0.02%
0.38%
Citadel Advisors LLC
546,872US$4.6m-41.7%no data
0.37%
Epoch Investment Partners, Inc.
531,896US$4.4m108%0.08%
0.35%
Woodline Partners LP
500,494US$4.2m-18.5%0.04%

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/10 19:02
End of Day Share Price 2025/01/08 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Aurinia Pharmaceuticals Inc. is covered by 22 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David MartinBloom Burton & Co.
Dae Gon HaBTIG
Neil MaruokaCanaccord Genuity